Kornimate/medical-research-clean huggingface dataset:
the effects of medical clowns in children undergoing blood tests

Conditions: Pain; Anxiety

Summary: the investigators hypothesized that the participation of therapeutic clowns in the pediatric emergency department procedure room would reduce anxiety, improve the level of cooperation children can provide and avoid some of the adverse effects.

research has demonstrated that cognitive psychological techniques, including distraction, can increase pain tolerance. humor can be an important intervention, able to reduce stress to both the child and the parent. in the last decade there has been a rapid growth in the presence of therapeutic clowns in hospital, particularly in pediatric settings. if therapeutic clowns are shown to positively affect any of the parameters being measured in this study, they should be included as aprt of the standard of care in the pediatric emergency setting.

Eligibility criteria:
inclusion criteria: * children needing venous blood sampling or the insertion of an intravenous canula exclusion criteria: * children whose blood work or intravenous line must be accomplished rapidly for therapeutic reasons * absence of a parent during the procedure * abnormal development according to parents

Keywords: medical clown pediatric emergency medicine emergency procedures
safety and effectiveness of bm-msc vs at-msc in the treatment of sci patients.

Conditions: Spinal Cord Injuries

Summary: spinal cord injury (sci) is a devastating condition that leads to permanent functional and neurological deficits in injured individuals. the limited ability of the central nervous system (cns) to spontaneously regenerate impairs axonal regeneration and functional recovery of the spinal cord. the leading causes are motor-vehicle crashes, sports-associated accidents, falls, and violence-related injuries. unfortunately, there is still no effective clinical treatment for sci. in recent years, tissue engineering and regenerative medicine based approaches have been proposed as alternatives for sci repair/regeneration. mesnchymal stem cells (msc) use in sci showed promising results in several studies. our aim is to assess and compare the safety and effectiveness of autologous bm-msc vs autologous at-msc in these patients.

the study will be conducted at cell therapy center (ctc) in jordan, where 14 sci patients meeting the inclusion criteria will be recruited and blindly divided into 2 groups of equal numbers. the first groups will be treated with autologous bm-msc, while the second group will be treated with autologous at-msc. the outcomes and improvements will be assessed using the american spinal injury association (asia) impairment scale (ais). magnetic resonance imaging (mri) will be performed at base line and after 12 months of the stem cell transplantation.

Eligibility criteria:
inclusion criteria: * complete spinal cord injury grade ais-a or -b, or incomplete c * at least 2 weeks since time of injury * cognitively unaffected * motivated for stem cell transplantation exclusion criteria: * reduced cognition * age under 18 years of above 70 years * significant osteoporosis in spine and/or joints * pregnancy (adequate contraceptive use is required for women in fertile age) * anoxic brain injury * neurodegenerative diseases * evidence of meningitis * positive serology for human immunodeficiency virus (hiv), hepatitis b virus (hbv), hepatitis c virus (hcv), or syphilis. * medical complications that contraindicate surgery, including major respiratory complications. * use of metal implants close to vascular structures (such as cardiac pacemaker or prosthesis) that contraindicate magnetic resonance imaging (mri). * other medical conditions which can interfere with stem cell transplantation * inability to provide informed consent.

Keywords: spinal cord injury mesenchymal stem cells
adolescent substance abuse: progressive treatment

Conditions: Substance Abuse

Summary: the purpose of this study is to find out more about how to provide effective further treatment for adolescents who have received six weeks of group therapy for substance-use problems and continue to use drugs. treatments used in the study include a group therapy (met/cbt), an individual therapy (cbt), and a family therapy (fft). the study will look at whether abstinence or a very low level of use is a better guide for deciding whether further treatment is needed, how well different combinations of treatment work to reduce substance use, and whether it is possible to predict in advance which adolescents will respond best to which types of treatment. study investigators expect that a treatment strategy using what is learned about these issues in the first half of the project to develop an "adaptive" treatment model will work better than a "fixed" treatment to reduce adolescent substance use.


Eligibility criteria:
inclusion criteria: 1. 13 to 18 years if age 2. meet dsm-iv (apa, 1994) diagnostic criteria for substance abuse or dependence 3. live in the albuquerque metropolitan area or surrounding communities 4. sufficient residential stability to permit probable contact at follow-up (e.g., not homeless at time of intake). exclusion criteria: 1. there is evidence of psychotic or organic state of sufficient severity to interfere with the understanding of study instruments and procedures 2. the adolescent is deemed dangerous to self or others during evaluation 3. services other than outpatient treatment are required for the adolescent (e.g., inpatient, detoxification) 4. marijuana use is reported as being less than 13% of days in the previous 90 days.

Keywords: adolescent substance abuse
evaluation of an igg deficiency rapid screening test: a performance study with primary immunodeficiency (pid) patients in tunisia

Conditions: Primary Immunodeficiency Diseases

Summary: to evaluate the usability and utility of the device, % agreement between the pid-rdt and the referent assay (serum/plasma), and % agreement between capillary blood and venous blood samples using the pid-rdt within confirmed pid patients prior to receipt of their monthly iv-ig treatment.


Eligibility criteria:
inclusion criteria: * must be 6 months of age. * the types of pid presenting for iv-ig therapy will include evaluation of pid rdt with human capillary blood (version 1.0) \| 8agammaglobulinemia (ag), hypogammaglobulinemia (hag), common variable immunodeficiency (cvid), and hyper igm syndrome (higm). exclusion criteria: -
covid-19 remote monitoring

Conditions: COVID-19; Cardiac Arrhythmias

Summary: the objective of the study is to assess the impact of remote cardiac and vital sign monitoring in patients with coronavirus disease (covid-19) in the outpatient setting.

the objective of the study is to assess the impact of remote cardiac and vital sign monitoring in patients with coronavirus disease (covid-19) in the outpatient setting. this study will enroll covid-19 positive patients previously evaluated at mount sinai hospital/mount sinai health system (mshs) and affiliated hospitals deemed appropriate for home monitoring. patients will be monitored remotely in the outpatient setting for 1-3 weeks following diagnosis and/or treatment for covid-19 at msh/mshs.

Eligibility criteria:
inclusion criteria: * patients diagnosed with coronavirus and determined to be eligible for home monitoring and self-care, and either 1. not admitted to the hospital, and permitted to recover at home 2. discharged from inpatient hospitalization, during the acute recovery period * 18 years old or older with the ability to understand the requirements of the study and sign the informed consent form (or able to provide over-the-phone verbal consent). exclusion criteria: n/a

Keywords: covid-19 cardiac arrhythmias atrial fibrillation telemetry
melatonin in reduction of chemotherapy-induced toxicity (mircit) trial

Conditions: Advanced Stage Cancer

Summary: meta-analysis of previous studies have shown that melatonin is a beneficial adjutant for reducing chemotherapy-induced toxicity; however no randomized, double-blind, placebo controlled trials have been conducted. this study evaluates the effect of melatonin in improving quality of life and reducing chemotherapy-induced toxicity in advanced cancer patients. this is a multi-center, randomized, double-blind, placebo controlled trial conducted in patients with histologically proven advanced non small cell lung, breast, head and neck or sarcoma cancer. mixed-block randomization, stratified by center and treatment scheme is used to divide eligible patients into three groups: melatonin 20 mg, 10 mg or matched placebo. the patients are required to take the studied drugs at night (after 21.00 pm) on the first day of chemotherapy and continue daily for six months. standard treatment is chemotherapy according to each center's standard protocol. study endpoints are qol (fact), adverse event frequency (ctcae), oxidative stress status, melatonin level, and survival.


Eligibility criteria:
inclusion criteria: * histologically proven advanced nsclc, breast, head and neck, sarcoma cancer eastern cooperative oncology group (ecog) performance status (ps) ≤ 2 * platelet count ≥100,000 cells/mm3 * white blood cell count ≥ 3,000 cell/mm3 * hemoglobin ≥ 10 g/dl * serum creatinine ≤ 1.5 mg/dl * bilirubin ≤ 2 mg/dl * ast ≤ 2.5 times upper limit of normal(uln)for subjects without metastases or ast ≤ 2.5 times unl for those with liver metastases * new york heart association grade ≤ 2 * written consent exclusion criteria: * patients who receive prior chemotherapy or biotherapy, radiotherapy or surgery within 1 month preceding randomization * patients who have more than one type of cancer or brain metastasis were excluded from the trial. * patients with moderate neuropathy (ctcae grade ≥ 2) * patients with an active infection, or uncontrolled complications (i.e. blood glucose \> 200 mg/dl, uncontrolled hypertension, unstable angina, history of congestive heart failure or history of myocardial infarction within one year).

Keywords: cancer melatonin adjuvant therapy quality of life survival adverse events oxidative stress
evaluation of a mindfulness resiliency training program for refugees living in jordan

Conditions: Mental Health Issue (E.G., Depression, Psychosis, Personality Disorder, Substance Abuse); Mental Health Wellness 1; War-Related Trauma

Summary: to estimate the efficacy of a structured, scalable and replicable psychosocial intervention targeting refugees living in jordan, amman who have been forced to flee their homes due to regional conflicts.

the study is designed to examine the effects of the mindfulness resiliency training program (mrtp) conducted at collateral repair project (crp) on the resilience of refugees. the study group and the control group will be recruited from refugees currently residing in amman, jordan who are participating in the mrtp at crp, an ongoing program independent of our study. in order to assess the effect of the mrtp on participant resiliency, the three survey tools described above will be used: 1. the strength and difficulties questionnaire (sdq) as a measure of the individual's degree of traumatization and 2. the child and youth resiliency measure (cyrm-12) (for adolescents) or the adult resiliency measure (arm-12) (for adults) as a measure of resiliency

Eligibility criteria:
inclusion criteria: * participants who will be recruited in the study are adult and adolescent (13-19 years) refugees, syrian and non-syrians, who are currently residing in amman, jordan who will be participating in the mrtp at crp. exclusion criteria: * jordanian refugees residing in amman, jordan.
the safety and effectiveness of cidofovir in the treatment of venereal warts in hiv-infected patients

Conditions: HIV Infections; Condyloma Acuminata

Summary: to evaluate the safety and tolerance of topical cidofovir (hpmpc) therapy for condyloma acuminatum in patients with hiv infection. to investigate whether topical hpmpc therapy can induce regression of condyloma acuminatum in patients with hiv infection.

four groups of 10 patients each receive topical hpmpc at 0.3 percent concentration for 5 or 10 days total or 1.0 percent concentration for 5 or 10 days total, followed by 2 weeks of rest. when six patients at a given dose and schedule have completed treatment and follow-up without significant toxicity, subsequent patients are entered at the next higher dose level. patients are evaluated twice weekly during treatment and once weekly during the rest period. hpmpc may be extended for up to two additional courses in patients who experience no significant toxicity.

Eligibility criteria:
inclusion criteria concurrent medication: allowed: * azt, ddi, ddc, d4t, or 3tc. * oral trimethoprim/sulfamethoxazole. * aerosolized pentamidine. * dapsone. * fluconazole. * rifabutin. * clarithromycin. patients must have: * hiv seropositivity. * mean cd4 count \>= 100 cells/mm3. * external anogenital condyloma acuminatum confirmed by biopsy, present for less than 1 year. note: * warts on anal, urethral, or vaginal mucosa will not be studied. exclusion criteria co-existing condition: patients with the following symptoms or conditions are excluded: * active lesions of genital herpes, other skin wounds, or active inflammatory skin disorders in the same area as warts to be treated. * active medical problems sufficient to hinder study compliance. concurrent medication: excluded: * podofilox or any podophyllum resin preparation. * liquid nitrogen treatment. * interferon alpha. * trichloracetic acid. * other treatments, topical or systemic, surgical or ablative, known to have anti-papilloma activity. * other investigative drugs (except d4t or 3tc) unless approved by the sponsor. patients with the following prior conditions are excluded: history of untreated syphilis or bowenoid papulosis. prior medication: excluded within 4 weeks prior to study entry: * treatment for anogenital warts. * immunomodulators (including interferons or systemic corticosteroids). * lymphocyte replacement therapy. * biologic response modifiers. substance abuse.

Keywords: aids-related opportunistic infections acquired immunodeficiency syndrome aids-related complex antiviral agents condylomata acuminata cidofovir
dual energy x-ray absorptiometry (dxa) comparison hip resurfacing versus total hip arthroplasty (tha)

Conditions: Osteoarthritis, Hip

Summary: this study compares the change (loss) of bone mineral density (bmd) that occurs in the proximal femur after hip resurfacing and total hip replacement.

this study compares the change (loss) of bone mineral density (bmd) that occurs in the proximal femur after hip resurfacing and total hip replacement. the goal is to evaluate the bone loss in the proximal femur resulting from hip resurfacing surgery and to compare this to the bone loss in the proximal femur resulting from total hip arthroplasty.

Eligibility criteria:
inclusion criteria: * age of at least 20 years * osteoarthritis * elective total hip arthroplasty / resurfacing * signed informed consent exclusion criteria: * osteoporosis * revisions * femoral dysplasia * trochanteric osteotomy * inflammatory arthritis * breast-feeding, pregnancy, or women of child-bearing potential without documentation of a negative pregnancy test and not utilizing contraception * patients with a history of having taken or currently taking pth, fluoride therapy or strontium ranelate or patients taking other chronic medications that in the investigator's opinion are known to affect bone mineral density in a substantial way * patients with severe medical condition(s) that in the view of the investigator prohibits participation in the study * use of any other investigational agent in the last 30 days

Keywords: total hip replacement hip resurfacing femoral remodeling bone loss bone mineral density bmd dxa dexa tha
effect of propolis or metformin administration on glycemic control in patients with type 2 diabetes mellitus

Conditions: Diabetes Mellitus, Type 2

Summary: the aim of this study was to evaluate the effect of propolis or metformin on glycemic control in patients with type 2 diabetes mellitus without pharmacological treatment. all patients received for 12 weeks propolis, metformin or placebo. fasting serum glucose, 2-h serum glucose after oral glucose tolerance test, glycated hemoglobin a1c, a metabolic profile, areas under the curve of glucose and insulin, insulinogenic index, stumvoll index, and matsuda index were measured.

a randomized, double-blind, placebo-controlled clinical trial of three pharmacological groups was carried out, with the participation of 36 patients with type 2 diabetes mellitus without pharmacological treatment. at the beginning and end of the study, fasting serum glucose, 2-h serum glucose after oral glucose tolerance test, glycated hemoglobin a1c, and a metabolic profile were measured. areas under the curve of glucose and insulin, total insulin secretion insulinogenic index), the first phase of insulin secretion (stumvoll index), and insulin sensitivity (matsuda index) were calculated. all patients received for 12 weeks two capsules a day, one before the first bite of breakfast and another before the first bite of dinner. 12 of them took propolis (300 mg), another 12 received metformin (850 mg), and 12 more placebo in the same pharmacological presentation. this protocol was approved by a local ethics committee and written informed consent was obtained from all volunteers. results are presented as mean and standard deviation. intra-group differences were evaluated using kruskal-wallis and mann-whitney u-tests, while inter-group differences were calculated with the wilcoxon test; p≤0.05 was considered significant.

Eligibility criteria:
inclusion criteria: * patients both sexes * age between 30 and 60 years * mild to moderate physical activity * stable body weight for at least 12 weeks prior to the study * bmi 25.0 - 34.9 kg/m2 * diabetes mellitus type 2 of recent diagnosis without pharmacological treatment, with one of the following criteria (fasting blood glucose levels \>126 mg/dl; or postprandial blood glucose levels after an oral glucose tolerance test with 75 of oral glucose \>200 mg/dl * informed consent signed exclusion criteria: * women with confirmed or suspected pregnancy * women under lactation and/or puerperium * previous treatment for glucose * fasting glucose ≥250 mg/dl * known uncontrolled renal, hepatic, heart or thyroid diseased * hypersensibility to ingredients of intervention * known allergies to bee stings or their derived products * triglycerides ≥500 mg/dl * total cholesterol ≥240 mg/dl

Keywords: diabetes mellitus type 2 glycemic control propolis metformin pharmacological treatment-naïve patients
new oral anticoagulants (noac) in stroke patients

Conditions: Stroke; Atrial Fibrillation

Summary: registry to explore characteristics, use and management of new oral anticoagulants (noac) and vitamin k antagonists (vka) treatment among patients with atrial fibrillation (af) and recent cerebrovascular disease in a "real-world" setting at a stroke centre.

registry to explore characteristics, use and management of new oral anticoagulants (noac) and vitamin k antagonists (vka) treatment among patients with atrial fibrillation (af) and recent cerebrovascular disease in a "real-world" setting at a stroke centre. special interest is payed to conditions not or only in part investigated in the large randomised controlled trials (rct) and that are specific to patients with cerebrovascular disease. this includes early start of noac treatment after recent stroke, very old patients, multimorbidity, patients with a history of intracranial haemorrhage (ich) and patient satisfaction and preferences with vka/noacs.

Eligibility criteria:
inclusion criteria: * signed informed consent form (icf) * existing or newly diagnosed af * recent (\< 3 month) stroke (ischemic or haemorrhagic) or tia (=index event) * treatment with noacs or vkas is continued, changed or initiated for prevention of ischemic events exclusion criteria: * patients not able or unwilling to sign icf * patient is, in the opinion of the investigator, unlikely to comply with the scheduled follow-up visits or is unsuitable for any other reason * patients who will not be anticoagulated

Keywords: new oral anticoagulants (noac) vitamin k antagonists (vka) cerebrovascular disease
investigation the efficacy of manual therapy and exercise in patients with glenohumeral arthritis

Conditions: Glenohumeral Arthritis

Summary: the aim of the investigator's study is to compare the efficacy of manual therapy and exercise practices compared to exercise practice in patients with glenohumeral arthritis. thirty volunteer patients will include into the study.

patients will randomly divide into two groups. a common exercise program was applied to both groups during 15 sessions. manual therapy techniques will apply to the manual therapy group in addition to exercise practices. patients will evaluate in terms of functional status, pain, range of motion, muscle strength and health-related quality before and after 5 weeks of treatment. also, patient's satisfaction from treatment will evaluate at the 5th week of the treatment. dash and ases forms for functional status, vas for pain, digital goniometer for range of motion, manual muscle test for muscle strength, sf-12 for health-related quality of life, and global rating of change (grc) scale for patient satisfaction will be used as evaluation criteria.

Eligibility criteria:
inclusion criteria: * 40 years and older patients * to be diagnosed with ghoa by specialist physician via mri, us or radiography and physical examination * unilateral shoulder pain lasting more than 2 months seen during daily living activities and at rest exclusion criteria: patients with: * severe arthrosis * tumor * cervical radiculopathy * emotional or cognitive problems * a neurological disease that causes muscle weakness on the shoulder * a skin disease that may affect upper extremity assessment. * frozen shoulder * thoracic outlet syndrome

Keywords: glenohumeral arthritis pain mobilisation physiotherapy rehabilitation
cangaroo® registry study

Conditions: Arrhythmias, Cardiac

Summary: a multi-center registry evaluating participants who receive cangaroo envelope or no envelope during their cied implantation

this prospective, multi-center study will enroll up to 500 participants who are undergoing their initial cied implant with either a cangaroo envelope or no envelope. once a participant is enrolled in one of the two cohorts, each participant will have their medical history data reviewed and data will be recorded in the crf including baseline demographics, medications, and diagnoses. the details of the cied procedure including any complications/aes that occur during the procedure will be captured on the appropriate crf. information collected at the follow-up visits will include documentation of post-procedure status, including any complications, adverse events, or revision/reoperation procedures that occur during the follow-up period. this information will also be collected for any unscheduled follow-ups, visits, or care encounters that occur up to 3 months post-procedure. for participants that agree and qualify for optional long-term follow-up, the same information will be collected at additional follow-up points every six months for up to five years.

Eligibility criteria:
inclusion criteria: 1. participants for whom this is their first cied implantation at a particular anatomical site. participants with a history of prior cied implants at other anatomical sites than the current site can be included, provided that the planned implant location for the current cied procedure is the first implant procedure at that site. 2. participants aged 18 years or older at time of enrollment. 3. participant is able and agrees to provide written informed consent and use of phi. exclusion criteria: 1. participants who have had one or more prior cied procedures (implantations or revisions) at the current device implant site. 2. participants under the age of 18 at time of enrollment.